USPTO serial 87478979
SILENCE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 4, 2018
- Examiner
- I, DAVID C
- Law office
- Historical data usage
What this means
Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.
Need help with SILENCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science; nucleic acid molecules for laboratory use; arrays of nucleic acid molecules for scientific and medical research; nucleic acid molecules mediating RNA interference for scientific and medical research | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations for use in the treatment of rare diseases, namely, iron overload disorders, acromegaly, metabolic diseases, cardiovascular disease, alcohol use disorder, delayed graft function and acute kidney injury; Pharmaceutical and veterinary preparations containing a nucleic acid for use in the treatment of rare diseases, namely, iron overload disorders, acromegaly, metabolic diseases, cardiovascular disease, alcohol use disorder, delayed graft function and acute kidney injury; Pharmaceutical and veterinary preparations containing a nucleic acid for mediating RNA interference for use in the treatment of rare diseases, namely, iron overload disorders, acromegaly, metabolic diseases, cardiovascular disease, alcohol use disorder, delayed graft function and acute kidney injury; all goods mentioned before not for gynaecological pharmaceutical preparations; nucleic acid molecules for medical or veterinary use | ACTIVE | — |
| 040 | [ treatment of materials by laser beam; treatment of materials, namely, the addition of polymer additives, radio opacifiers and antimicrobial agents to render them ecogenic, radiopaque or bacteriostatic; custom manufacture of nucleic acids for third parties; custom manufacture of lipids for third parties; custom manufacture of nucleic acid containing composition for third parties; custom manufacture of transformed biological cells to the specification of third parties ] | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services, namely, research and design in the fields of RNA interference and delivery of pharmaceuticals; industrial analysis and research services in the fields of biological research, molecular biology, genetics and microbiology; design and development of computer hardware and software; scientific and technological services, namely, research in the field of RNA interference and delivery of pharmaceuticals; industrial analysis and research services in the field of RNA interference and delivery of pharmaceuticals | ACTIVE | — |
| 044 | Medical Services; veterinary services; hygienic and beauty care for human beings and animals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Silence Therapeutics GmbH
- Other trademarks owned by Silence Therapeutics GmbH
- Other trademarks owned by Silence Therapeutics GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SILENCE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 16, 2025 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Jun 16, 2025 | 8.OK | REGISTERED - SEC. 8 (6-YR) ACCEPTED | The USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline. |
| Jun 12, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 4, 2025 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Sep 4, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 4, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 19, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 19, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 30, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 15, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 8, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 8, 2018 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| May 8, 2018 | ISMR | WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST | — |
| May 8, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 8, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 18, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 4, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 4, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 4, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 4, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 4, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 2, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 28, 2018 | ALIE | ASSIGNED TO LIE | — |
| Mar 14, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 14, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 7, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 14, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 10, 2017 | NWAP | NEW APPLICATION ENTERED | — |